|View printer-friendly version|
|March 11, 2007 1:32 p.m.|
|Teva Receives First U.S. Approval For Generic UNIRETIC® Tablets|
Jerusalem, Israel, March 11, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDAfor Moexipril HCland HydrochlorothiazideTablets, 7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg. Shipment of these products will begin immediately.